Related Experiment Video
Updated: Dec 7, 2025
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma
María-Victoria Mateos1, Joan Bladé2, Sara Bringhen3
1Hospital Clínico Universitario de Salamanca/IBSAL/CIC, 37007 Salamanca, Spain.
Abstract:
Despite the availability of new therapies that have led to improved outcomes for patients with multiple myeloma, most patients will eventually relapse. With triplet and even quadruplet combination therapies becoming standard in the first and second line, many patients will have few treatment options after second-line treatment. Melflufen (melphalan flufenamide) is a first-in-class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. Once inside the tumor cells, melflufen is hydrolyzed by peptidases to release alkylator molecules, which become entrapped. Melflufen showed anti-myeloma activity in myeloma cells that were resistant to bortezomib and the alkylator melphalan. In early phase studies (O-12-M1 and HORIZON [OP-106]), melflufen plus dexamethasone has demonstrated encouraging clinical activity and a manageable safety profile in heavily pretreated patients with relapsed/refractory multiple myeloma, including those with triple-class refractory disease and extramedullary disease. The Phase III OCEAN study (OP-104) is further evaluating melflufen plus dexamethasone in patients with relapsed/refractory multiple myeloma. The safety profile of melflufen is characterized primarily by clinically manageable hematologic adverse events. Melflufen, with its novel mechanism of action, has the potential to provide clinically meaningful benefits to patients with relapsed/refractory multiple myeloma, including those with high unmet needs.
Insights
Melflufen, a novel peptide-drug conjugate, shows promise for relapsed/refractory multiple myeloma patients. Early studies indicate clinical activity and a manageable safety profile in heavily pretreated individuals.
Area of Science:
- Oncology
- Pharmacology
- Hematology
Background:
- Multiple myeloma patients often relapse despite new therapies, leaving limited options after second-line treatment.
- Triplet and quadruplet regimens are standard, increasing the need for novel treatments in relapsed/refractory settings.
- Melflufen (melphalan flufenamide) is a first-in-class peptide-drug conjugate targeting aminopeptidases.
Purpose of the Study:
- To evaluate the clinical activity and safety of melflufen plus dexamethasone in relapsed/refractory multiple myeloma.
- To assess melflufen's efficacy in heavily pretreated patients, including those with triple-class refractory disease and extramedullary disease.
- To investigate melflufen's potential as a treatment option for patients with high unmet needs.
Main Methods:
- Early phase studies (O-12-M1 and HORIZON) evaluated melflufen plus dexamethasone.
- Ongoing Phase III OCEAN study (OP-104) further assesses this combination in relapsed/refractory multiple myeloma.
- Melflufen's mechanism involves targeted delivery of alkylating agents into tumor cells via peptidases.
Main Results:
- Melflufen demonstrated anti-myeloma activity, including in cells resistant to bortezomib and melphalan.
- Early studies showed encouraging clinical activity and a manageable safety profile in heavily pretreated patients.
- Hematologic adverse events were the primary safety concerns, characterized as clinically manageable.
Conclusions:
- Melflufen plus dexamethasone exhibits potential for patients with relapsed/refractory multiple myeloma.
- The novel mechanism of action offers a new therapeutic avenue for patients with limited treatment options.
- Melflufen may provide clinically meaningful benefits, addressing high unmet needs in this patient population.
More Related Videos
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
